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Abstract
Background: Mesenchymal stem cells (MSCs) can differentiate into osteoblasts and adipocytes and conditions causing bone
loss may induce a switch from the osteoblast to adipocyte lineage. In addition, the expression of Runx2 and the PPARc2
transcription factor genes is essential for cellular commitment to an osteogenic and adipogenic differentiation,
respectively. Modified lipoproteins derived from the oxidation of arachidonate-containing phospholipids (ox-PAPCs:
POVPC, PGPC and PEIPC) are considered important factors in atherogenesis.
Methodology: We investigated the effect of ox-PAPCs on osteogenesis and adipogenesis in human mesenchymal stem cells
(hMSCs). In particular, we analyzed the transcription factor Runx2 and the PPARc2 gene expression during osteogenic and
adipogenic differentiation in absence and in presence of ox-PAPCs. We also analyzed gene expression level in a panel of
osteoblastic and adipogenic differentiation markers. In addition, as circulating blood cells can be used as a ‘‘sentinel’’ that
responds to changes in the macro- or micro-environment, we analyzed the Runx2 and the PPARc2 gene expression in MSCs-
like and ox-PAPC levels in serum of osteoporotic patients (OPs). Finally, we examined the effects of sera obtained from OPs
in hMSCs comparing the results with age-matched normal donors (NDs).
Principal findings: Quantitative RT-PCR demonstrated that ox-PAPCs enhanced PPARc2 and adipogenic gene expression
and reduced Runx2 and osteoblast differentiation marker gene expression in differentiating hMSCs. In OPs, ox-PAPC levels
and PPARc2 expression were higher than in NDs, whereas Runx2 was lower than in ND circulant MSCs-like.
Conclusions: Ox-PAPCs affect the osteogenic differentiation by promoting adipogenic differentiation and this effect may
appear involved in bone loss in OPs.
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Introduction
Osteoporosis is a common age-related skeletal disease charac-
terized by loss of bone mass which increases bone fragility. Bone
remodelling plays a major role in the maintenance of the
mechanical integrity of the skeleton and involves a coordinated
process of bone formation (promoted by osteoblasts) and bone
resorption (promoted by osteoclasts) [1].
Osteoblasts derive from mesenchymal stem cells (MSCs) that
are multipotent progenitor cells with the capacity to differentiate
into connective tissue cells [2]. Mesenchymal stem cells can
differentiate into osteoblasts but also in adipocytes and there is an
inverse relationship between the formation of adipocytes and
osteoblasts [3,4]. Conditions associated with bone deficiency such
as ovariectomy, treatment with glucocorticoids and immobiliza-
tion are correlated with an increase of adipocytes in bone marrow
[5,6]. One hypothesis explaining bone loss suggests an imbalance
in the differentiation of osteoblast and adipocyte progenitors at the
expense of the osteoblasts; this hypothesis have been confirmed by
histomorphometric analyses that have shown adipocytic replace-
ment of the bone marrow in patients with osteoporosis [7].
Previous studies have shown that atherosclerotic calcification
and osteoporosis may coexist in the same patient [8]. Hyperlip-
idaemia is associated with progression of coronary calcification
and reduces bone mineral density in mice [9]. In vitro and in vivo
studies show that oxidized lipids promote mineralization of the
vascular cells and reduce mineralization of bone cells, inhibiting
differentiation of pre-osteoblasts [8].
Recent findings suggest that postmenopausal women with
atherogenic lipid profile show an elevated risk of osteopenia with
respect to those with normal lipid profiles [10]. From another
point of view, modified lipoproteins, particularly oxidized
phospholipids, such as ox-PAPCs were considered an important
factor in atherogenesis. Previous studies demonstrated ox-PAPCs
inhibit spontaneous osteoblastic differentiation and mineralization
of calvarial pre-osteoblasts and bone marrow stromal cells [8,11].
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cellular commitment to a specific differentiation lineage [12] and
activation of phenotype-specific transcription factors, such as
osteoblast-specific Runx2/Cbfa1 and adipocyte-specific PPARc2,
determines lineage commitment [13,14].
Runx2, a master gene for osteoblast differentiation, is a member
of the runt family of transcription factors and its expression is
necessary to differentiate and to activate osteoblasts [15].
Peroxisome proliferator-activated receptor gamma (PPARc), a
member of the nuclear receptor family of transcription factors, is
important in the control of adipocyte development and in the
glucose and fatty acid metabolism [16] and its activation has a
pivotal role in selection of adipogenesis over osteoblastogenesis
[17].
It has been shown that PPARc2 is able to convert stromal cells
from an osteoblastic phenotype to differentiated adipocytes and it
can suppress the expression of Runx2 and osteoblast specific genes
[18]. In addition, MSCs obtained from control and osteoporotic
women show differences in their capacity to differentiate into
osteogenic and adipogenic lineage [19].
On the basis of these acknowledges, we postulated that the gene
expression alteration of Runx2 and PPARc2 may disrupt the
balance between osteo and adipo progenitors in osteoporotic
patients with respect to normal individuals and that ox-PAPCs
may contribute to these alterations.
In our previous study, we demonstrated the possibility to obtain
mesenchymal stem cells-like (MSCs-like) from peripheral blood
(PB-MSCs-like) by two-step method that leads the depletion of
hematopoietic component [20] and the selection of circulant
progenitors.
In order to investigate gene expression alterations and the
contribute of ox-PAPCs in the pathogenesis of osteoporosis, we
analyzed, in vitro, the gene expression during osteogenic and
adipogenic differentiation in mesenchymal stem cells in presence
or absence of ox-PAPCs. In addition, we analyzed the mRNA
expression of both Runx2 and PPARc2 in circulant MSCs-like,
the levels of ox-PAPCs in serum of osteoporotic patients (OPs) and
normal donors (NDs) and the adipogenic and osteogenic gene
expression in hMSCs cultured with sera obtained from OPs and
NDs.
Our study showed that ox-PAPC exposure affects the osteogenic
and adipogenic differentiation of hMSCs in vitro. Furthermore, ox-
PAPC levels resulted higher in OPs with respect to NDs and the
sera obtained from OPs affect the differentiation process in hMSc.
Results
Effects of ox-PAPC treatment in mesenchymal stem cells
To assess the effect of the ox-PAPC treatment, mesenchymal
stem cells with specific differentiation medium in absence and in
presence of ox-PAPCs ranging from 5 to 20 mg/ml were
evaluated. Cell viability as measured by the XTT assay was
similar during adipogenic and osteogenic differentiation with and
without ox-PAPC treatment (Figure 1).
When gene expression analysis was performed, we observed
that the treatment with 10 mg/ml up to 24 h during adipogenic
Figure 1. Cell viability in hMSCs, expressed in percentage. XTT test was performed in hMSCs treated with and without ox-PAPCs during
adipogenic (A) and osteogenic (B) differentiation (n=3).
doi:10.1371/journal.pone.0020363.g001
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after 48 h the treatment induced an upregulation of this gene with
respect to untreated cells (Table 1A) suggesting that further
modification, internalization, or processing of ox-PAPCs may be
necessary to obtain this effect. The adipogenic differentiation
specific gene (AdipoQ and Lep) resulted up-regulated with respect to
the untreated cells only after 1 week of ox-PAPC treatment
(Table 1B and Table S1).
In addition, when cells were cultured for 72 h in presence of ox-
PAPCs during adipogenic differentiation, OIL Red O staining
showed an increase of intracellular lipid-filled droplets in a dose
dependent manner (Figure 2). In particular, the area of oil red O
staining was 0.1%60.05 in the control and 1.2%60.6, 1.8%60.5
and 2.1%60.5 at 5 mg/ml, 10 mg/ml and 20 mg/ml, respectively.
After 1 week of ox-PAPC treatment, the percentage of area
stained by oil red O was: 18%62 in control, and 25%62.7,
34%61.6 and 42%63.6 at 5 mg/ml, 10 mg/ml and 20 mg/ml,
respectively.
On the contrary, during osteogenic differentiation the ox-PAPC
treatment induced a downregulation on Runx2 gene expression
from 24 h and this effect was present also after 48 h of treatment
(Table 2A). In particular, gene expression of Runx2 during
osteogenic differentiation was downregulated in a dose dependent
manner with ox-PAPC treatment for 48 h at a concentration
ranging from 5 to 20 mg/ml (Table 2A).
After 48 h and 1 week of osteogenic differentiation in absence
or in presence ox-PAPCs in hMSCs, we performed the expression
analyses for bone specific genes. According to Runx2 levels at the
beginning of osteogenic commitment, we observed a downreg-
ulation of collagen type 1 (Colia1), osteonectin (Sparc) and
osteopontin (Spp1) gene expression in hMSCs cultured with
osteogenic differentiation medium in presence of ox-PAPCs at a
concentration ranging from 5 to 20 mg/ml only after 1 week
(Table 2B and Table S1). When we evaluated the osteocalcin
expression by immunofluorescence, we observed a significant
protein level reduction 10 days after ox-PAPC treatment
(Figure 3).
To evaluate the effects of oxPAPCs in undifferentiated cells, we
treated hMSCs cultured in medium w/o adipogenic and
osteogenic differentiation factors with ox-PAPCs at a concentra-
tion ranging from 0 (controls) to 20 mg/ml.
When we performed the expression analysis for adipogenic and
osteogenic genes, we observed a significant increase of PPARc2
gene after 1 week of treatment (Table 3C). All other genes tested
didn’t change the value of expression with respect to untreated
controls (Table 3A and 3B). The level of AdipoQ and Lep genes
were less expressed in all conditions tested.
Densitometric results in OPs and NDs and circulant
progenitor cell phenotype
Densitometric results are showed in Table 4. OP patients
showed bone densitometric values lower than normal donors at all
skeletal sites evaluated.
The isolated circulant progenitor cells from osteoporotic
patients and normal donors expressed the cluster differentiation





+ resulted 0.5% (60.07)
in osteoporotic patients vs 0.47% (60.08) (p=NS), CD45
+ 2.25%
(60.3) vs 2.29 (60.45) (p=NS). In addition, the mRNA related to
osteoblast (Colia1 and Spp1) and adipocyte (AdipoQ, and Lep) specific
markers were not detectable in circulant MSCs-like. In fact, as
previously reported (20), these circulant MSCs-like obtained by
depletion method don’t contain well differentiated osteoblastic
cells. In addition, cells were negative also for AdipoQ and Lep
expression. However, these cells were positive for osteogenic and
adipogenic transcription factor genes (Runx2 and PPARc,
respectively) suggesting an early phase of their commitment.
Transcription factor gene expression in circulant
MSCs-like and level of ox-PAPCs in peripheral blood
Results of this study revealed that PPARc2and Runx2 mRNA have a
different expression in MSCs-like of osteoporotic patients with respect
to aged matched normal donors. All patients and normal donors were
females and no smokers. Peripheral blood was collected and MSCs-like
were isolated by depletion method for the total RNA extraction and for
reverse transcription in cDNA. Figure 4 shows the expression analysis
of the PPARc2 and Runx2 genes by the real-time PCR. The difference
fold change of expression of PPARc2andRunx2 mRNA (normalized by
using three different housekeeping genes, GAPDH, b2 microglobulin,
and beta-actin genes, respectively) in PB-MSCs-like of OPs compared
to NDs were 1.2860.14 and 0.760.07, respectively. The expression of
PPARc2 mRNA in PB-MSCs-like of OPs was significantly higher than
NDs (p,0.005), whereas the Runx2 expression in osteoporotic patients
resulted lower than in normal donors (p,0.001).
All three chemical compounds (POV/PAPC, PG/PAPC and
PEIP/PAPC) were detectable in serum of osteoporotic patients
(1.35 ng/mg, 0.6 ng/mg, 3.55 ng/mg, respectively) and in normal
donors (1.2 ng/mg, 0.52 ng/mg, 2.98 ng/mg, respectively), even
if only PG/PAPC resulted significantly higher in OPs than in NDs
(p,0.05) (Fig. 5 and Table S2).
Table 1. Fold change mRNA levels in hMSCs treated with ox-PAPCs during adipogenic differentiation.
A
(PPARc2) Ox-PAPCs 5 mg/ml Ox-PAPCs 10 mg/ml Ox-PAPCs 20 mg/ml
24 h treatment 1.03 1.02 1.10
48 h treatment 1.05 1.38* 1.37*
B
1 week
PPARc2 1.18 1.42* 1.47*
AdipoQ 1 1.24* 1.25*
Lep 1.08 1.28* 1.3*
*p,0.01.
doi:10.1371/journal.pone.0020363.t001
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PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e20363Figure 2. OIL Red O staining. When the hMSCs were cultured for 72 h in presence of ox-PAPCs during adipogenic differentiation, they showed a
dose dependent significant increase of lipid-folled droplets (p,0.05). (original magnification 206, insert 406). The percentage of area stained with
OIL Red O (red droplets) was quantified by using the IMAGE J Software.
doi:10.1371/journal.pone.0020363.g002
Table 2. Fold change mRNA levels in hMSCs treated with ox-PAPCs during osteogenic differentiation.
A
(Runx2) Ox-PAPCs 5 mg/ml Ox-PAPCs 10 mg/ml Ox-PAPCs 20 mg/ml
24 h treatment 1.04 0.64* 0.65*
48 h treatment 0.94 0.56* 0.45**
B
1 week Ox-PAPCs 5 mg/ml Ox-PAPCs 10 mg/ml Ox-PAPCs 20 mg/ml
Runx2 0.87 0.42** 0.44**
Colia1 0.82 0.54* 0.42**
Sparc 0.85 0.54* 0.42**
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differentiation
To evaluate the effects of sera obtained from OPs or NDs
during differentiation in MSCs, we used randomly pooled sera
either from OPs and NDs, as described in material and method
sections. Under these conditions, cells were cultured for 24 h, 48 h
and 1 week before cell viability and gene expression analysis
evaluation.
Under all conditions assayed, no viability differences were
observed with respect to pooled sera from OPs and from NDs
(data not shown).
When gene expression was analyzed, until 24 h of sera
treatment the expression levels for all genes tested were similar
in all cases (Table 5). After 48 h of incubation with sera from OPs
or NDs in cells cultured in adipogenic medium, levels of expression
of PPARc2 gene were similar (Table 5).
However, after 1 week of cell culture, the expression of PPARc2
resulted higher in hMSCs with respect to NDs sera in presence of
OP sera (Table 5).
During osteogenic differentiation, the effects of OP sera in
osteogenic gene expression were more relevant (Table 5) than in
adipogenic gene expression. Values of each serum pool are
reported in Table S3.
Figure 3. Osteocalcin immunofluorescence. After 10 days of ox-PAPC treatment during osteogenic differentiation, osteocalcin expression
decreased in hMSCs in a dose dependent manner (n=3; p,0.05). (original magnification 206).
doi:10.1371/journal.pone.0020363.g003
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To analyze the effect of ox-PAPCs in the osteogenic and
adipogenic differentiation, we used an in vitro model based on
commercial MSCs to eliminate the potential effect of different
circulant growth factors and cytokines.
Our data showed that the ox-PAPC treatment affects the
osteogenic and adipogenic differentiation by altering the tran-
scription factor and the lineage related gene expression in a dose
dependent manner and by promoting the adipogenic differenti-
ation at the expense of osteogenic differentiation. Even if fold
variations of the specific gene expressions were significant,
differences were small and this aspect could limit the biological
relevance of the results. Nevertheless, a different level of Oil red O
Table 3. Fold change mRNA levels in undifferentiated hMSCs treated with ox-PAPCs.
A
24 h treatment Ox-PAPCs 5 mg/ml Ox-PAPCs 10 mg/ml Ox-PAPCs 20 mg/ml
PPARc2 1.05 1.01 1.12
Runx2 1.05 0.98 1.01
Spp1 1.05 0.95 1.01
Colia1 0.98 0.97 0.97
Sparc 1.01 0.98 1.02
B
48 h treatment
PPARc2 1.06 1.16 1.18
Runx2 0.97 1.02 1.01
Spp1 1.03 0.98 1.02
Colia1 1.01 1.02 0.96
Sparc 1.01 1.04 1.02
C
1 week treatment
PPARc2 1.08 1.18 1.31*
Runx2 1.01 0.98 0.97
Spp1 1.05 0.97 1.01
Colia1 0.98 0.97 1.02
Sparc 1.02 1.01 0.98
*p,0.05.
doi:10.1371/journal.pone.0020363.t003
Table 4. Densitometric and biochemical data of the study
population.
Variables OP ND p
Number 34 25
Age (years) 59.1265,61 58,3968,20 ns
BMD spine (g/cm
2) 0,73260,04 0,95860,14 *
T sc lumbar spine (SD) 22,8760,36 21.0061,07 *
Z sc lumbar spine (SD) 21,5260,53 0,2161,26 *
BMD femoral neck (g/cm
2) 0,6460,06 0,73560,09 *
T sc femoral neck (SD) 21,7960,67 21,0760,63 *
Z sc femoral neck (SD) 20,5660,77 0,0260,7 *
BMD total hip (g/cm
2) 0,7560,06 0,85360,05 *
T sc total hip (SD) 21,5160,65 20,8160,54 *
Z sc total hip (SD) 20,6360,70 0,0760,65 *
Cholesterol (mg/dl) 203658 212644 ns
C Reactive Protein (CRP, mg/L) ,3 ,3n s
Values are expressed as mean 6 SD.
*p,0.001 between PO and ND.
doi:10.1371/journal.pone.0020363.t004
Figure 4. mRNA fold change. PPARc2 and Runx2 in circulant MSCs-
like from normal donors (NDs) and osteoporotic patients (OPs),
*p ,0.005 vs NDs and **p,0.001 vs NDs, respectively. The fold change
was obtained by using three different housekeeping genes (GAPDH, b2
microglobulin, beta-actin).
doi:10.1371/journal.pone.0020363.g004
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control and treated samples are consistent with observed
differences in gene expression, thus supporting a biological role
of the ox-PAPCs. Indeed, ox-PAPC effects on gene expression
promoted an adipogenic phenotype with increased intracellular
lipid-filled droplets and lessened the osteogenic phenotype, as
confirmed by decreased osteocalcin levels.
It has been reported that the adipogenic differentiation depends on
PPARc2expression associated withtheavailability of PPARcligand/
activator [21]. The same authors showed that oxidized derivatives of
linoleic acid present in oxidized LDL promoted adipogenic
differentiation by activating PPARc in an in vitro model [22]
suggesting ox-PAPCs as potential activators of PPARc. In addition,
another study in vitro focused on the research of potential PPARc
activators showed that ox-PAPCs and its components POVPC and
PGPC were able to activate PPAR response element-driven report.
Ox-PAPCs might move to the nucleus for binding PPAR receptor or
might activate PPAR receptor by its hydrolytic products [23].
It is known the ox-PAPCs may have opposite effects on different
cells. Bear and coworkers showed that ox-LDL may promote
osteogenic differentiation in vascular smooth muscle cells with
consequent vascular calcification in vitro [24]. On the contrary, in a
previous study, in addition to effects of lipid oxidation products on
calcifying vascular cells, it was shown that treatment of
preosteoblastic MC3T3-E1 cells with MM-LDL inhibited their
differentiation, as indicated by inhibition of alkaline phosphatase
activity and calcification [8]. These evidences support epidemio-
logical data suggesting a possible link between cardiovascular
diseases associated to lipidic alterations and osteoporosis. Howev-
er, the relationship between skeleton and cardiovascular system is
certainly complex and involved several aspects, as suggested by
recent findings [25,26] and by the fact that not all osteoporotic
patients have lipid disorders and vice versa.
The interactions between peripheral blood cells and the entire
body lead the possibility that changes occurring in association with
Figure 5. Ox-PAPCs in peripheral blood. A) Representation of autoxidised reaction of 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine.
B) Levels of POVPC, PGPC and PEIPC (ox-PAPCs) in sera of normal donors (NDs) and osteoporotic patients (OPs). PGPC form resulted significantly
higher in osteoporotic patients with respect to normal donors (p,0.05).
doi:10.1371/journal.pone.0020363.g005
Table 5. Fold change mRNA levels in hMSCs treated with OP
vs. ND pooled sera during adipogenic (PPARc2, ADIPOQ and
LEP) and osteogenic (RUNX2, SPP1, COLIA1, SPARC)
differentiation.
24 h treatment 48 h treatment 1 week treatment
PPARc2 1.03 1.11 1.3*
AdipoQ 1.01 1.02 1.18
Lep 1.01 1.02 1.12
Runx2 0.98 0.92 0.92
Colia1 0.97 0.84 0.83
Sparc 1.01 0.80* 0.78*
Spp1 1.05 0.76* 0.72*
*p,0.05.
doi:10.1371/journal.pone.0020363.t005
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alterations in gene expression in blood cells reflective of the
stimulus. A recent study suggested that circulating blood cells can
be used as a ‘‘sentinel’’ that responds to changes in the macro- or
micro-environment in organs, making the blood an ideal surrogate
tissue for diagnostic analyses [27].
Our previous study demonstrated that circulating MSCs-like
showed an abnormal osteogenic differentiation in osteoporotic
patients [28]. In effect, we observed a downregulation of the
master gene Runx2 and the downstream factor Osterix and also
the mRNA of Sparc, Spp1 and Colia1 resulted lower in osteoporotic
patients with respect to age-matched normal donors. In addition,
we observed a significant correlation between bone density and
osteoblastic gene expression, suggesting a direct relationship
between bone mass and osteoblast differentiation and confirming
an involvement of osteoblastic lineage in the mechanism of bone
loss [28].
Osteoblasts and adipocytes have a common mesenchymal
progenitor and an inverse relation between the two lineages under
some pathological conditions has already been suggested [29].
Adipocyte differentiation is controlled by peroxisome proliferators-
activated receptors (PPARs), members of the nuclear receptor
superfamily [30] and analyses of home- and heterozygous PPARc-
deficient mice have suggested that PPARc may determine the fate
of osteo-adipocyte precursor during differentiation events [31].
Runx2 (also known as Cbfa1) is known to be essential for
osteoblastic differentiation, because its null mutation in mice
exhibits the complete lack of bone [32]. Runx2 expression is
upregulated in proliferative chondrocytes and it is early expressed
in osteoblastic differentiation. This gene can be stimulated by
multiple signal transduction pathways [33] and it can directly
stimulate the transcription of osteoblast-related genes [34].
Mesenchymal stem cells obtained from bone marrow of donors
and osteoporotic patients showed differences in their capacity to
differentiate into the osteogenic and adipogenic lineage [35] and,
considering that osteoblastic and adipogenic differentiation
pathway are regulated jointly, this observation suggests that
marrow adipogenesis could be involved in some osteogenic
disorders [30,36].
On the basis of these findings, we hypothesized that adipogenic
and osteogenic transcription factor gene expression in mesenchymal
precursors may be different in osteoporotic patients with respect to
normal donors. According to this suggestion, we observed a different
expression profile of transcription factor genes (PPARc2 and Runx2)i n
circulant MSCs-like of osteoporotic patients with respect to normal
donors. Indeed, the overexpression of PPARc2 mRNA was associated
to a downregulation of Runx2 mRNA in osteoporotic patients with
respect to normal donors. It is known that in age-related and
postmenopausalosteoporosis, adipogenicdifferentiationofprogenitor
cells increases at the expense of osteogenic differentiation [37] and
our results showed that the different levels of Runx2 and PPARc2 gene
expression in MSCs-like may reflect this shift. Although the causes
inducing this shift are not yet clearly identified, the fate of progenitors
cells may be determined by paracrine and autocrine factors acting on
the control of differentiation master regulators. In addition, difference
in the composition of fatty acid may contribute to this shift since it has
been demonstrated that specific fatty acids are able to activate the
adipogenesis master regulator PPARc [3]. This is in agreement with
our results as both the gene expression of PPARc2andthelevelsofox-
PAPCs are higher in osteoporotic patients with respect to normal
donors.
It has been shown that PPARc2, upon activation by ligand
binding, regulates the transcription of adipocyte-specific genes
[38] and its activation by free fatty acid, prostaglandin J2 and the
thiazolidinedione class of antidiabetic drugs induces adipogenesis
[3].
Products of lipid and lipoprotein oxidation including minimally
oxidized low density lipoprotein (MM-LDL) inhibit the differen-
tiation and mineralization of preosteoblasts in vitro [8].
The results of the present study, showed that all the three ox-
PAPC forms, (POV/PAPC, PG/PAPC and PEIP/PAPC) are
detectable in serum either in osteoporotic patients either in normal
donors. However, only PG/PAPC resulted significantly higher in
osteoporotic patients than in normal donors.
It is known that atherogenic lipoproteins and phospholipids,
including midly oxidized LDL and ox-PAPCs, inhibit osteogenesis
in bone marrow stromal cells via the ERK pathway [11].
According to these findings, in addition to an increase of ox-
PAPCs in serum of osteoporotic patients, our data showed that the
master gene of osteogenic differentiation Runx2 was significantly
lower in their circulant MSCs-like. Moreover, the serum obtained
from OP patients, affects the differentiation process by altering the
transcription factor Runx2 and PPARc2 gene expression. Even if
we cannot exclude the role of various cytokines circulating in
peripheral blood, nevertheless we hypothesize that ox-PAPCs
could be involved in osteogenic differentiation.
Conclusions
The alterations in transcription factor gene expression during
differentiation triggered by ox-PAPCs support the hypothesis that
modified lipoproteins are involved in inhibition of early osteogenic
differentiation from mesenchymal stem cells. This inhibition can
promote adipogenic cell population and this aspect can support
the hypotesis that lipid alteration is associated with osteoporosis. In
addition, data in vivo showing a different transcription gene
expression pathway in association with a higher ox-PAPC levels in
osteoporotic patients with respect to normal donors suggest that
oxidation lipid products may contribute, at least in part, to the fate
of progenitor cells with a consequent bone loss. In fact, it is known
that oxidized lipids accumulate within the skeleton and, in
particular, within the perivascular space of Haversian canals in
osteoporotic patients [39]. However, further studies should be




Written informed consent was obtained from all participants
and the study was approved by the Ethical Committee of Azienda
Ospedaliera Universitaria Integrata of Verona, Italy.
Patients
We selected 34 postmenopausal osteoporotic patients (OPs)
consequently referred to our Metabolic Bone Disease Centre from
January 2006 until November 2008. We compared these patients
with 25 normal postmenopausal women (NDs) matched for age
and anthropometric parameters. None of patients and volunteers
was taking any therapy before the enrollement.
All women included in the study underwent a densitometric
(DXA) measurement at the lumbar spine and hip (Hologic QDR
Discovery Acclaim, Waltham, Massachusetts, USA) and osteopo-
rosis was diagnosed according to WHO parameters, considering as
the cut-off that a lumbar spine or femoral T score lower than 22.5
SD [40].
Biochemical evaluations were performed in all osteoporotic
patients in order to rule out secondary causes of osteoporosis (S-
calcium [Ca], S-phosphate [P], urinary calcium rate [CaE],
Runx2 and PPARc2 in Osteoporosis
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type I collagen [CTX], alkaline phosphatase [ALP], 25-hydro-
xyvitamin D [VitD]).
Normal donors inclusion criteria were a T sc.22 SD without
any history of bone fractures. In addition, in both osteoporotic
patients and normal donors groups, cholesterol levels and CRP (C
Reactive Protein) were evaluated.
Women with history of premature menopause (,45 year old),
traumatic fractures in the previous 12 months or with diseases or
using drugs able to affect bone or calcium-phosphate metabolism
were excluded from the study.
Cell culture
Human mesenchymal stem cells obtained from PromoCell (C-
12974 International pbi, Milano, Italia) derived from normal
human bone marrow and are tested for their ability to differentiate
in vitro into adipocytes, chondrocytes and osteoblasts (as per
Promocell).
We used commercial MSCs to have a sufficient quantity of cells
to perform all experiments and to eliminate the potential effect of
different circulant growth factors and cytokines.
Cells were cultured in Mesenchymal Stem Cell Growth
Medium containing Basal Medium and SupplementMix (from
PromCell) and supplemented with 100 U/ml penicillin and
100 U/ml streptomycin (from Invitrogen).
For use in the experiments the hMSCs were plated at a density of
5610
4 cells per well into 48-well plates or 5610
3 cells per well into
96-well plates. After two days, the medium was removed and
osteogenic or adipogenic differentiation was induced with Mesen-
chymal Stem Cell Osteogenic Differentiation Medium or Stem Cell
Adipogenic Differentiation Medium (all from PromoCell).
Ox-PAPC treatment
PAPCs was oxidized by transferring 1 mg in 100 mlo f
chloroform to a clean glass test tube and evaporating the solvent
under a stream of nitrogen. The lipid residue was allowed to
autoxidize while exposed to air for 72 h at room temperature. The
extent of oxidation was monitored by flow injection ESI-MS. After
oxidation the medium used in the experiments was added.
The cells were cultured with specific differentiation medium in
absence and in presence of ox-PAPCs ranging from 5 to 20 mg/ml.
After the treatment, the cells were used for analyses.
Treatment of hMSCs with human sera
We used the hMSCs purchased from PromoCell in order to
analyze the effects of sera obtained from OPs and from NDs
during adipogenic and osteogenic differentiation. We used
commercial MSCs to eliminate the potential effect of different
circulant growth factors and cytokines.
In particular, we randomized sera from OPs and NDs, as
reported in previous studies [41–44]. Briefly, serum samples from
34 OPs were divided into six groups. In the same way, serum
samples from 25 NDs were randomly divided into five groups.
Each serum pool was obtained with equal volumes from all
patients or all donors within the group.
We added the pooled sera to osteogenic and adipogenic
medium at 10% concentration. Cells were plated at a density of
5610
4 cells per well into 48-well plates and cultured for 24 h, 48 h
and 1 week before gene expression analysis.
Cell viability
Cell viability was evaluated by a colorimetric assay based on the
reduction of the tetrazolium salt XTT (sodium 3I-[1-phenyla-
mino- carbonyl-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene
sulfonic acid hydrate) by mitochondrial dehydrogenase of viable
cells to a formazan dye (Cell proliferation kit II — XTT Roche).
Briefly, 5610
3 cell/well in 96 microtitre plates were treated, once
80% confluence was reached, at concentrations ranging from 5 to
20 mg/ml of ox-PAPCs for 24 h, 48 h and 1 week. After the
incubation period, 100 ml XTT labelling mixture was added to
each well and incubated at 37uC under humidified atmosphere of
5% CO2 for 4 h. The spectrophotometric absorbance of the
samples was measured using a microtitre plate (ELISA) reader at a
wave length of 450 nm.
Oil red O staining
The cells, cultured with adipogenic medium in absence or in
presence of ox-PAPCs ranging from 5 to 20 mg/ml, were stained
with Oil Red O and the total area of red pixels in the Oil Red O-
stained droplets/cell was determined by using the IMAGE J image
analysis program developed at the National Institutes of Health. In
particular, the mean 6 SD of red stained area, measured at
magnification of 406 in six cell-containing slides and three
different field/slide from each group, were expressed as percentage
respect to total area.
Immunofluorescence
For evaluation of osteocalcin, cells were grown in slide with
osteogenic medium in absence or in presence of ox-PAPCs
ranging from 5 to 20 mg/ml for 10 days under humidified
atmosphere of 5% CO2 at 37uC; then, cultured cells were fixed for
20 min in 2% paraformaldehyde and stored a 220uC.
The slides were washed three times in PBS and permeabilized
with 0.2% Triton X-100 in PBS. After three washs in PBS, cells
were blocked for 1 h in blocking buffer containing 1% of bovine
serum albumin (BSA) in PBS. Cells were washed again and
incubated overnight with the primary antibody (osteocalcin mouse
monoclonal antibody, Santa Cruz Biotechnology, Inc Switzer-
land). After three washes in PBS, cells were incubated for 2 h in
fluoroisothiocyanate (FITC) conjugated secondary antibody (goat
antimouse igG, Santa Cruz Biotechnology, Inc Switzerland). Cells
were washed again three times with PBS and counterstained with
4,6 diamidino-2-phenylindole (DAPI) to detect nuclei and
mounted with aqueus mounting medium.
To express in a semiquantitative way the levels of protein, the
total area of green pixels (corresponding to osteocalcin positive
area) was determined by using the IMAGE J image analysis
program developed at the National Institutes of Health as above
described.
Sample collection for serum and circulant MSCs-like
A sample of peripheral blood was obtained by venipuncture from
each of 34 OPs and 25 NDs. For each OP and ND serum and cells
were obtained. The serum was obtained from 10 ml of fresh blood,
obtained by venipuncture, by centrifugation at 4006g. the serum
was harvested and separated into aliquots and frozen at 280uC
until the use. MSC-like cells were isolated by starting from 50 ml
using a method including two ficoll procedures to deplete
hematopoietic cells by antibodies cocktail. Firstly, mononuclear
cells from 50 ml of heparinizated peripheral blood by gradient
centrifugation (Ficoll GE) were obtained. The enriched cell pellet
(concentrated mononuclear cells) was mixed with 4 ml of additional
peripheralblood (from the same patient) as red cells are necessary to
apply 200 ml antibodies cocktail (RosetteSep Mesenchymal Enrich-
ment Cocktail; StemCells); this mix contains bi-specific antibody
complexes against red blood cells (glycophorin A), CD3, CD14,
CD19, CD38 and CD66b positive cells (Stem Cell Technologies
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red blood cells in the sample, causing them to pellet together when
centrifuged over the second ficoll.
The enriched cells obtained were washed in PBS and analyzed
for transcripts expression.
Analysis of cell phenotype
We analyzed the cell phenotype at the RNA level for CD3,
CD14, CD19, CD45, and CD34 markers, as previously described
[45]. This method allows the phenotypic analysis in small number
of cells obtained by stringent stem-cell purification strategies [45].
In addition, we evaluated in circulant MSCs-like also the mRNA
expression of osteoblast (Colia1, and Spp1) and adipocyte
(AdipoQ and Lep) markers. RNA extraction and RT Real-Time
PCR were performed in circulant MSCs-like samples from
osteoporotic patients and normal donors as following described.
Total RNA extraction
Total RNA was extracted from each cell pellet from MSCs-like
of OPs and NDs and from in vitro cell cultures by using the
RNAeasy minikit (Quiagen) with DNAse I treatment. The amount
of extracted RNA was quantified by measuring the absorbance at
260 nm. The purity of the RNA was checked by measuring the
ratio of the absorbance at 260 and 280 nm, where a ratio ranging
from 1.8 to 2.0 was taken to be pure. The absence of degradation
of the RNA was confirmed by RNA electrophoresis on a 1.5%
agarose gel containing ethidium bromide.
Reverse transcription
First-strand cDNA was generated using the First Strand cDNA
Synthesis Kit (GE Healthcare), with random hexamers, (GE
Healthcare) according to the manufacturer’s protocol. RT product
was aliquoted in equal volumes and stored at 280uC.
Real time RT-PCR
PCRs were performed in a total volume of 50 ml containing 16
Taqman Universal PCR Master mix, no AmpErase UNG and 5 mlo f
cDNA from each sample; pre-designed, Gene-specific primers and
probe sets for each gene (CD3, Hs00174158_m1; CD14,
Hs02621496-s1; CD19, Hs00174333_m1; CD45, Hs00174541_
m1; CD34, HS00156373_m1; Runx2, Hs00231692_m1; PPARC,
Hs01115513_m1; B2M, Hs999999_m1; COLLAGEN, TYPE I,
ALPHA 1 (Colia1) Hs00164004_m1; OSTEONECTIN (Sparc)
Hs00234160_m1; OSTEOPONTIN (Spp1) Hs00167093_m1; ADI-
PONECTIN (AdipoQ) Hs00605917_m1; LEPTIN (Lep)
Hs00174877_m1;, GAPDH, 0802021; beta-actin, 0807024; Applied
Biosystems) were obtained from Assay-on-Demande Gene Expression
Products (Applied Biosystems). Real Time RT-PCR reactions were
carried out in two-tube system and in multiplex. The Real Time
amplifications included 10 minutes at 95uC (AmpliTaq Gold activat-
ion), followed by 40 cycles at 95uC for 15 seconds and at 60uCf o r
1 minute. Thermocycling and signal detection were performed with
ABI Prism 7300 Sequence Detector; (Applied Biosystems). Signals
were detected according to the manufacturer’s instructions. This
technique allows the identification of the cycling point where PCR
product is detectable by means of fluorescence emission (Threshold
cycle or Ct value). As previously reported, the Ct value correlates to
the starting quantity of target mRNA [46]; we selected the DRn in the
exponential phase of amplification plots to determine the Ct values
and to obtain the linearity of calibration curves.
To evaluate the cell phenotype, mRNA quantification was
analyzed by Relative Standard Curve Method. The amount of
cDNA in each sample, obtained as average of triplicates and
normalized with beta-2-microglobulin (B2M), was determined
from standard curve derived from a four cDNA dilution series
(from peripheral blood cells) and the results are expressed as
percentage for expression of cluster differentiation marker genes.
The criteria for evaluate the presence of mRNA related to
osteoblast and adipocyte markers are based on the mRNA
detectability in circulant MSCs-like by using the osteogenic and
adipogenic differentiated MSC line as a control.
To compare relative mRNA levels in the OP and ND and in
vitro treated cells, the gene expression was calculated after
normalization against the housekeeping genes (B2M, GAPDH
and b-actin) using the relative fold expression differences [47].
Ct values for each reaction were determined using TaqMan SDS
analysis software. For each amount of RNA tested triplicate Ct values
were averaged. Because Ct values vary linearly with the logarithm of
the amount of RNA, this average represents a geometric mean. In
addition, we considered as relevant a fold change ,0.8 and .1.2,
even if also smaller changes were statistically significant.
Phospholipid extraction
A total lipids fraction was obtained after liquid-liquid extraction
of 120 ml specimen of blood serum with chloroform-methanol
mixture (3:1, v/v), according to the method of Folch [48]. Blood
serum was shaken for 10 min at room temperature, then, 0.9%
sodium chloride solution was added there to, the extract was
shaken for 30 s and immediately centrifuged (15006g/5 min/
4uC). The lower layer of the lipid extract was separated and dried
under N2, and then dissolved in 40 ml of a chloroform-methanol
mixture (1:4 v/v, 0.1% BHT).
Analysis of oxidized phospholipid levels
We analyzed the three ions, m/z 594.3 POVPC, 610.2 PGPC
and828.5PEIPCasNP-HPLCfractionthatcontainedthesespecies
possessed biological activity in peripheral blood [49]. Samples in
40 ml of chloroform-methanol mixture were injected onto a C8
column (4,66250 mm, particle size 5 mm, Waters Spherisorb)
equilibrated in 95% MeOH containing 1 mM ammonium acetate.
The column was eluted isocratically at 0.3 ml/min. Mass-
spectrometry was performed using an Agilent 1100 Ion Trap mass
analyzer, fitted with an ESI source. Phospholipids were analyzed as
the protonated molecule [M+H
+] in positive ion mode; the mass
spectrometer was set to scan Single ion Monitoring on m/z 594.3
(POVPC), 610.3 (PGPC), 782.5 (PAPC) and 828.5 (PEIPC). The
results are expressed as ng/mg PAPCs.
Statistical methods
The experiments were performed in triplicate and repeated for
three times. Results were expressed as means 6 SD. The statistical
analysis was assessed by T-Student test for independent samples.
In all analyses, a p value less than 0.05 (p,0.05) was considered a
significant difference. Statistical analyses were performed by using
SPSS for Windows version 16.0 (SPSS Inc., Chicago, IL, USA).
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